Liquid Biopsy for Pediatric Brain Tumors

Diagnostic Rationale And Biofluid Selection

Central Nervous System (CNS) tumors are the leading cause of pediatric cancer mortality.
Traditional surgical biopsies for deep-seated tumors, such as Diffuse Midline Gliomas (DMG) or Diffuse Intrinsic Pontine Gliomas (DIPG), carry massive risks of permanent neurological morbidity or hemorrhage.
Spatial tissue biopsies fail to capture massive tumor heterogeneity and evolutionary changes under therapeutic pressure.
Cerebrospinal Fluid (CSF) Supremacy: The intact Blood-Brain Barrier (BBB) severely restricts the shedding of circulating tumor DNA (ctDNA) into systemic plasma, yielding diagnostic sensitivities below 5%.
CSF bathes the tumor directly, providing a highly enriched ctDNA source with diagnostic sensitivities exceeding 85% to 90% via safe lumbar puncture or Ommaya reservoir access.

Circulating Tumor DNA (ctDNA): Fragmented DNA analyzed for point mutations, copy number variations (CNVs), and epigenetic methylation patterns.
Extracellular Vesicles (EVs): Microvesicles containing functional proteins and microRNAs that mirror the physiological state of the parental tumor.
Circulating Tumor Cells (CTCs): Intact cells used primarily for evaluating leptomeningeal dissemination patterns in high-grade malignancies.

Technology	Clinical Utility And Performance
Digital Droplet PCR (ddPCR)	Absolute quantification of target DNA; detects the pathognomonic H3K27M mutation in DMG with near 90% sensitivity at diagnosis.
Nanopore Sequencing & lpWGS	Provides rapid turnaround (48–72 hours) for detecting major CNVs and gene amplifications, such as MYC in medulloblastoma or PDGFRA in secondary gliomas.
M-PACT (AI Integration)	Methylation-based Predictive Algorithm for CNS Tumors utilizes an Artificial Intelligence (AI) deep neural network trained on over 5,000 profiles. Achieves 92% classification accuracy for embryonal CNS tumors directly from sub-nanogram CSF ctDNA, eliminating tissue requirements.

Clinical Domain	Application Details
Inoperable Tumors	Provides molecular confirmation for surgically inaccessible lesions (e.g., detecting BRAF-KIAA1549 fusions in diffuse leptomeningeal glioneuronal tumors) to initiate targeted MEK inhibitors.
Pseudoprogression Differentiation	Falling or undetectable ctDNA levels differentiate treatment-induced radiation necrosis (pseudoprogression) from true tumor progression, preventing unnecessary rescue therapies.
Minimal Residual Disease (MRD)	Serial CSF sampling tracks variant allele frequencies, identifying molecular relapse months before visible structural recurrence or leptomeningeal seeding appears on surveillance MRI.

WHO Alignment: Liquid biopsy fulfills the 2021 WHO CNS5 classification mandates requiring molecular diagnostics when physical biopsy is anatomically contraindicated.
Indian Context: Comprehensive genomic sequencing remains astronomically cost-prohibitive in Low- and Middle-Income Countries (LMICs).
Pragmatic Strategy: Tertiary Indian centers (e.g., Tata Memorial Hospital, AIIMS) successfully utilize highly specific, affordable ddPCR panels targeting high-yield regional mutations (e.g., H3K27M or MYD88).
Resource Optimization: Replacing high-risk neurosurgical biopsies with simple lumbar punctures serves as a massive cost-saving measure in developing healthcare systems, allowing resource reallocation toward definitive chemotherapy or palliative care.